Back to Results
First PageMeta Content
Proteobacteria / Vaccines / Meningococcal disease / Neisseria meningitidis / Neisseria / Meningitis / Meningococcal septicaemia / NmVac4-A/C/Y/W-135 / Meningococcal vaccine / Bacteria / Microbiology / Bacterial diseases


Meningococcal B Vaccine Dr. Taj Jadavji Professor, Departments of Pediatrics, Microbiology, Immunology & Infectious Diseases Faculty of Medicine University of Calgary
Add to Reading List

Document Date: 2014-08-22 15:53:54

Open Document

File Size: 2,27 MB

Share Result on Facebook

City

Washington / DC / Edmonton / Wellington / Stockholm / /

Company

Pfizer / Novartis / NL (N=42) BC (N=127) AB / Serogroup / Sanofi / Merging Laboratory / /

Country

Canada / United Kingdom / Sweden / New Zealand / Wales / /

Facility

Medicine University / /

MedicalCondition

Invasive Meningococcal Disease / disease / invasive disease / population Invasive Meningococcal Disease / invsaive meningococcal disease / meningococcal disease / deafness / renal failure / Meningococcemia Severe Late-Stage Meningococcal Infection / epidemic disease / /

MedicalTreatment

amputations / Vaccination / /

Organization

Public Health England Meningococcal Reference Unit / Pediatrics / Microbiology / Immunology & Infectious Diseases Faculty / IMD / European Centre for Disease Prevention and Control / University of Calgary / Medicine University / Ministry of Health / /

Position

Professor / Departments / Infectious Disease Consultant / /

ProvinceOrState

Alberta / Quebec / Ontario / /

RadioStation

Core / /

Region

Western Canada / /

SocialTag